Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

Chen X, Kosoglou T, Statkevich P, Kumar B, Li J, Dockendorf MF, Wang G, Lowe RS, Jiang J, Liu H, Wang Z, Cutler DL, Hu P.

Int J Clin Pharmacol Ther. 2014 Aug 20. [Epub ahead of print]

PMID:
25138682
[PubMed - as supplied by publisher]
2.

Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.

Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, Kim K, Miller SD.

Chest. 2013 Dec;144(6):1795-802. doi: 10.1378/chest.13-0505.

PMID:
24077095
[PubMed - indexed for MEDLINE]
3.

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Wang Z, Xuan F, Lin WH, Troyer MD, Tendolkar A, Cutler DL.

Eur J Clin Pharmacol. 2013 Oct;69(10):1761-7. doi: 10.1007/s00228-013-1541-5. Epub 2013 Jul 16.

PMID:
23857248
[PubMed - indexed for MEDLINE]
4.

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.

Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B, Wittmer BA.

Int J Chron Obstruct Pulmon Dis. 2013;8:107-16. doi: 10.2147/COPD.S36592. Epub 2013 Mar 4.

PMID:
23525511
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.

Kosoglou T, Statkevich P, Kumar B, Xuan F, Schiller JE, Johnson-Levonas AO, Young S, Cutler DL.

J Clin Pharmacol. 2013 May;53(5):540-9. doi: 10.1002/jcph.20. Epub 2013 Feb 20.

PMID:
23426761
[PubMed - indexed for MEDLINE]
6.

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.

Cutler DL, Tendolkar A, Grachev ID.

J Clin Pharm Ther. 2012 Oct;37(5):578-87. doi: 10.1111/j.1365-2710.2012.01349.x. Epub 2012 Jun 7.

PMID:
22676397
[PubMed - indexed for MEDLINE]
7.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.

Statkevich P, Kosoglou T, Preston RA, Kumar B, Xuan F, Trusley C, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1501-8. doi: 10.1007/s00228-012-1269-7. Epub 2012 Apr 19.

PMID:
22527342
[PubMed - indexed for MEDLINE]
8.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Kosoglou T, Zhu Y, Xuan F, Black L, Johnson-Levonas AO, Martinho M, Statkevich P, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1509-16. doi: 10.1007/s00228-012-1271-0. Epub 2012 Apr 5.

PMID:
22476387
[PubMed - indexed for MEDLINE]
9.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Jul;68(7):1049-56. doi: 10.1007/s00228-012-1217-6. Epub 2012 Feb 8.

PMID:
22315147
[PubMed - indexed for MEDLINE]
10.

Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects.

Cutler DL, Tendolkar A, Grachev ID.

J Clin Pharmacol. 2012 Nov;52(11):1698-703. doi: 10.1177/0091270011428321. Epub 2011 Dec 13.

PMID:
22167566
[PubMed - indexed for MEDLINE]
11.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.

Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912.

PMID:
22011284
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.

Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL.

Eur J Clin Pharmacol. 2012 Mar;68(3):291-300. doi: 10.1007/s00228-011-1127-z. Epub 2011 Oct 4.

PMID:
21969227
[PubMed - indexed for MEDLINE]
13.

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Kosoglou T, Reyderman L, Tiessen RG, van Vliet AA, Fales RR, Keller R, Yang B, Cutler DL.

Eur J Clin Pharmacol. 2012 Mar;68(3):249-58. doi: 10.1007/s00228-011-1120-6. Epub 2011 Sep 21.

PMID:
21935705
[PubMed - indexed for MEDLINE]
14.

Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

Gupta SK, Kolz K, Cutler DL.

Eur J Clin Pharmacol. 2011 Jun;67(6):591-9. doi: 10.1007/s00228-010-0972-5. Epub 2010 Dec 16.

PMID:
21161196
[PubMed - indexed for MEDLINE]
15.

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.

Kosoglou T, Zhu Y, Statkevich P, Triantafyllou I, Taggart W, Xuan F, Kim KT, Cutler DL.

Eur J Clin Pharmacol. 2011 May;67(5):483-92. doi: 10.1007/s00228-010-0955-6. Epub 2010 Dec 1.

PMID:
21120461
[PubMed - indexed for MEDLINE]
16.

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.

Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI.

Cancer Chemother Pharmacol. 2011 Feb;67(2):455-63. doi: 10.1007/s00280-010-1488-5. Epub 2010 Oct 24.

PMID:
20972873
[PubMed - indexed for MEDLINE]
17.

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.

Kosoglou T, Cutler DL, Staudinger H, Herron JM.

Chest. 2010 Jan;137(1):115-21. doi: 10.1378/chest.09-0235. Epub 2009 Sep 11.

PMID:
19749003
[PubMed - indexed for MEDLINE]
18.

Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

Zhu Y, Statkevich P, Cutler DL.

Int J Clin Pharmacol Ther. 2007 Oct;45(10):539-47.

PMID:
17966839
[PubMed - indexed for MEDLINE]
19.

Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.

Gupta SK, Swan SK, Marbury T, Smith W, Schwartz S, Kolz K, Cutler DL.

Br J Clin Pharmacol. 2007 Dec;64(6):726-32. Epub 2007 Jun 6.

PMID:
17555463
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy.

Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL.

J Clin Pharmacol. 2007 May;47(5):604-12. Epub 2007 Mar 30. Erratum in: J Clin Pharmacol. 2007 Aug;47(8):1061.

PMID:
17400820
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk